Incretin Atlas·MoleculesTrialsOutcomesTimelinePipelineAboutMedical Adviser's Group
Incretin Atlas › Molecules › Zovaglutide

Zovaglutide

GLP-1 (ultra-long-acting, monthly) · s.c. · QL Biopharm

Data cut 12 November 2026 · page built 16 November 2026 · 0 trial arms · 0 trials with results · 1 registered trials · see on the pipeline board

Summary

Also known as
ZT002, QL Biopharm
Mechanism
GLP-1 (ultra-long-acting, monthly)
Route
s.c.
Company
QL Biopharm
Highest development stage
phase 3
Status (as of data cut)
Phase 3 in obesity (HORIZON-1, China, started Jan 2026) verify
Next milestone
HORIZON-1 readout

Sources for the status

Indications: regulatory and evidence status

IndicationCodeStatusEvidence
Obesity2 phase 3 ongoingPhase 3 HORIZON-1 (China) ongoing; phase 2 met its primary endpoint (company, 2025)HORIZON-1
T2D0 no data
CV outcomes0 no data
CKD0 no data
HFpEF0 no data
MASH0 no data
Sleep apnoea0 no data
Knee OA0 no data
Alzheimer's0 no data

4 = approved / in a label (FDA, EMA or NMPA), 3 = positive phase 3, 2 = phase 3 ongoing or completed without public results, 1 = phase 2 or signal only, 0 = no data, −1 = negative phase 3/4. L = label, P = PubMed, T = registry.

Trial arms: weight, HbA1c and tolerability

No trial arms with extracted efficacy or tolerability data yet.

Registered trials (1)

From ClinicalTrials.gov and the atlas registry sweep; phase 3 and outcome trials first.

TrialIndicationPhaseStatusStart → primary completionnResultRegistry
HORIZON-1
A Study of Zovaglutide in Subjects With Overweight or Obesity (HORIZON-1)
ObesityPhase 3active not recruiting2026-01 → 2027-05755active not recruitingNCT07230119

Primary sources

No source recorded.

How to cite this page

Medical Adviser's Group. Incretin Atlas: Zovaglutide. Data cut 12 November 2026. https://docs.mdwrt.app/infographics/incretin-atlas/zovaglutide/ Data: doi:10.5281/zenodo.23473913. Accessed 16 November 2026.

Cite the primary publication for any single result; every value above links to it.